Novartis India is currently trading at Rs. 829.00, up by 29.90 points or 3.74% from its previous closing of Rs. 799.10 on the BSE.
The scrip opened at Rs. 820.00 and has touched a high and low of Rs. 844.00 and Rs. 815.60 respectively. So far 1,11,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 869.60 on 11-Jun-2015 and a 52 week low of Rs. 539.95 on 27-Mar-2015.
Last one week high and low of the scrip stood at Rs. 844.00 and Rs. 760.00 respectively. The current market cap of the company is Rs. 2,652.00 crore.
The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 2.38% and 22.62% respectively.
Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.
The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.
Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
| Company Name | CMP |
|---|---|
| Redington | 222.80 |
| Adani Enterprises | 2505.65 |
| Amrapali Industries | 18.21 |
| Rashi Peripheral | 530.50 |
| PDS | 300.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: